Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Pluri Inc. (PLUR) has strengthened its intellectual property portfolio with two new patents for 3D expansion of immune cells, granted by the USPTO and Israel. The patents specifically cover MAIT (Mucosal-Associated Invariant T) cell expansion technologies in large-scale bioreactors.
The company's placental MAIT cells platform aims to address solid tumor treatment, targeting the immune cell engineering market (projected at $11.7B by 2030) and cancer immunotherapy market ($136B in 2025). These cells offer unique advantages over conventional T cells, including lower alloreactivity and enhanced tumor-targeting capabilities.
Pluri's IP estate now encompasses over 250 patents pending, allowed, and granted. The technology enables commercial-scale production of 'off-the-shelf' immune cell therapies, with applications extending to Tumor Infiltrating Lymphocytes (TILs).
Pluri Inc. (PLUR) ha rafforzato il suo portafoglio di proprietà intellettuale con due nuovi brevetti per l'espansione 3D delle cellule immunitarie, concessi dall'USPTO e da Israele. I brevetti coprono specificamente le tecnologie di espansione delle cellule MAIT (Cellule T Invarianti Associate alle Mucose) in bioreattori su larga scala.
La piattaforma di cellule MAIT placentari dell'azienda mira a affrontare il trattamento dei tumori solidi, mirando al mercato dell'ingegneria delle cellule immunitarie (stimato in 11,7 miliardi di dollari entro il 2030) e al mercato dell'immunoterapia contro il cancro (136 miliardi di dollari nel 2025). Queste cellule offrono vantaggi unici rispetto alle cellule T convenzionali, inclusa una minore alloreattività e capacità potenziate di targeting dei tumori.
Il patrimonio di proprietà intellettuale di Pluri comprende ora oltre 250 brevetti in attesa, concessi e autorizzati. La tecnologia consente la produzione su scala commerciale di terapie cellulari immunitarie 'pronte all'uso', con applicazioni che si estendono ai Linfociti Infiltranti Tumorali (TIL).
Pluri Inc. (PLUR) ha fortalecido su cartera de propiedad intelectual con dos nuevas patentes para la expansión 3D de células inmunitarias, otorgadas por la USPTO e Israel. Las patentes cubren específicamente tecnologías de expansión de células MAIT (Células T Invariantes Asociadas a las Mucosas) en biorreactores a gran escala.
La plataforma de células MAIT placentarias de la empresa tiene como objetivo abordar el tratamiento de tumores sólidos, enfocándose en el mercado de ingeniería de células inmunitarias (proyectado en 11,7 mil millones de dólares para 2030) y el mercado de inmunoterapia contra el cáncer (136 mil millones de dólares en 2025). Estas células ofrecen ventajas únicas sobre las células T convencionales, incluyendo menor aloreactividad y capacidades mejoradas de direccionamiento hacia tumores.
El patrimonio de propiedad intelectual de Pluri ahora abarca más de 250 patentes en espera, permitidas y otorgadas. La tecnología permite la producción a escala comercial de terapias celulares inmunitarias 'listas para usar', con aplicaciones que se extienden a los Linfocitos Infiltrantes Tumorales (TIL).
Pluri Inc. (PLUR)는 USPTO와 이스라엘에서 부여된 면역 세포의 3D 확장을 위한 두 개의 새로운 특허로 지적 재산 포트폴리오를 강화했습니다. 이 특허는 대규모 바이오리액터에서 MAIT(점막 연관 불변 T) 세포 확장 기술을 구체적으로 다룹니다.
회사의 태반 MAIT 세포 플랫폼은 고형 종양 치료를 목표로 하며, 면역 세포 공학 시장(2030년까지 117억 달러로 예상)과 암 면역 요법 시장(2025년까지 1360억 달러)에서의 경쟁력을 목표로 합니다. 이 세포들은 기존 T 세포에 비해 낮은 이식 반응성과 향상된 종양 표적화 능력 등 독특한 장점을 제공합니다.
Pluri의 지적 재산은 현재 250개 이상의 특허를 보유하고 있으며, 대기 중인, 허가된 및 부여된 특허를 포함합니다. 이 기술은 상업적 규모의 '즉시 사용 가능한' 면역 세포 치료제를 생산할 수 있게 하며, 종양 침윤 림프구(TIL)에까지 응용됩니다.
Pluri Inc. (PLUR) a renforcé son portefeuille de propriété intellectuelle avec deux nouveaux brevets pour l'expansion 3D des cellules immunitaires, accordés par l'USPTO et Israël. Les brevets couvrent spécifiquement les technologies d'expansion des cellules MAIT (Cellules T Invariantes Associées aux Mucoses) dans des bioréacteurs à grande échelle.
La plateforme de cellules MAIT placentaires de l'entreprise vise à traiter les tumeurs solides, en ciblant le marché de l'ingénierie des cellules immunitaires (prévu à 11,7 milliards de dollars d'ici 2030) et le marché de l'immunothérapie contre le cancer (136 milliards de dollars en 2025). Ces cellules offrent des avantages uniques par rapport aux cellules T conventionnelles, notamment une réactivité allogénique réduite et des capacités de ciblage des tumeurs améliorées.
Le patrimoine de propriété intellectuelle de Pluri comprend désormais plus de 250 brevets en attente, accordés et autorisés. La technologie permet la production à échelle commerciale de thérapies cellulaires immunitaires 'prêtes à l'emploi', avec des applications s'étendant aux lymphocytes infiltrants tumoraux (TIL).
Pluri Inc. (PLUR) hat sein Portfolio an geistigem Eigentum mit zwei neuen Patenten für die 3D-Erweiterung von Immunzellen gestärkt, die von der USPTO und Israel gewährt wurden. Die Patente decken speziell die Technologien zur Erweiterung von MAIT (Mucosa-assoziierte invariant T) Zellen in großflächigen Bioreaktoren ab.
Die Plattform für plazentare MAIT-Zellen des Unternehmens zielt darauf ab, die Behandlung solider Tumoren anzugehen, und richtet sich an den Markt für Immunzelltechnik (voraussichtlich 11,7 Milliarden Dollar bis 2030) und den Markt für Krebsimmuntherapie (136 Milliarden Dollar im Jahr 2025). Diese Zellen bieten einzigartige Vorteile gegenüber herkömmlichen T-Zellen, einschließlich geringerer Alloreaktivität und verbesserter Tumorzielerreichung.
Das geistige Eigentum von Pluri umfasst nun über 250 anhängige, genehmigte und erteilte Patente. Die Technologie ermöglicht die kommerzielle Produktion von 'sofort einsatzbereiten' Immunzelltherapien, die auch auf tumorinfiltrierende Lymphozyten (TIL) angewendet werden können.
- Secured two new strategic patents for 3D immune cell expansion technology
- Technology enables commercial-scale production of off-the-shelf cell therapies
- Targeting large markets: $11.7B immune cell engineering and $136B cancer immunotherapy
- Extensive IP portfolio with over 250 patents pending, allowed, and granted
- No immediate revenue generation from these patents
- Commercialization timeline and regulatory approval process remain uncertain
Insights
Pluri's newly granted patents in the US and Israel significantly strengthen their intellectual property position in the competitive cell therapy landscape. These patents specifically protect their 3D bioreactor technology for expanding MAIT cells - a specialized T cell subset with unique advantages for solid tumor targeting. This is strategically important as it addresses a critical manufacturing bottleneck that has MAIT cell therapeutic development.
The timing is particularly advantageous following recent FDA approvals for TIL and TCR-T therapies, creating a favorable regulatory environment for cell-based cancer immunotherapies. With over 250 patents now in their portfolio, Pluri has built substantial barriers to entry in this specialized field.
The technology's dual application for both MAIT cells and TILs expands Pluri's potential market reach and partnership opportunities. Their placental-derived approach offers key advantages over traditional blood-derived therapies, potentially reducing rejection issues while improving persistence in patients.
This patent strengthens Pluri's position to capture value in the rapidly growing immune cell engineering market (
These patent grants represent a significant validation of Pluri's technological approach in the competitive cellular immunotherapy landscape. Their proprietary 3D expansion system addresses a fundamental challenge in MAIT cell therapy development - the ability to produce these cells at commercial scale.
The focus on MAIT cells is particularly noteworthy as they represent a potential next-generation approach to solid tumors, which remain largely resistant to current CAR-T therapies. MAIT cells' natural tumor-homing capabilities and reduced risk of Graft versus Host Disease create a compelling therapeutic profile that could translate to best-in-class efficacy and safety.
From a market positioning perspective, Pluri is targeting the intersection of two high-value segments: allogeneic ("off-the-shelf") therapies and solid tumor treatment. This aligns perfectly with where major pharma companies are placing strategic bets, enhancing partnership potential.
The expansion capability for both MAIT cells and TILs provides important strategic optionality and risk diversification. This dual-platform approach creates multiple potential revenue streams through either licensing deals, manufacturing partnerships, or internal product development programs targeting different oncology indications.
- Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancers
- Pluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patients
- Pluri’s MAIT platform addresses the global immune cell engineering market, projected to reach approximately
$11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 billion in 2025 - In addition to MAIT cells, Pluri’s platform also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), further broadening the scope of potential immune cell therapies in cancer immunotherapy and attracting attention in the growing TILs-focused research space
HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a patent covering the Company’s immune cell expansion technologies. This patent specifically includes MAIT cells, a unique subset of T cells that are crucial in helping the body fight infection and repair tissue. Additionally, Pluri was issued a patent in Israel, which mirrors previously granted US patent. Pluri’s total intellectual property (“IP”) estate now includes over 250 patents pending, allowed, and granted.
Pluri’s placental MAIT cells are unique, unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical need. MAIT cells offer unique advantages compared to conventional T cells, holding immense potential for immunotherapy, but until now, their expansion has been a challenge, primarily due to the difficulty in expanding them outside of the human body. Leveraging two decades of cell expertise, Pluri believes that it has overcome the challenge to unlock the full potential of MAIT cells.
The granted patents titled “System and Methods For Immune Cells Expansion and Activation In Large Scale” focus on a system and method for culturing and/or activating immune cells in a large scale, within Pluri’s proprietary 3D cell expansion bioreactors.
“These latest granted patents, which further fortify our growing IP around MAIT cells, are very timely as the U.S. Food and Drug Administration has recently approved Tumor-infiltrating lymphocytes (TILs) and T Cell Receptor-engineered T cell (TCR-T) therapies for the treatment of solid cancers. We believe that MAIT cells represent an emerging field with significant potential in immunotherapy and we believe that our unmatched ability to scale production of MAIT cells, combined with our growing IP portfolio, position Pluri for collaborations that can potentially deliver immune therapies to people in need,” stated Yaky Yanay, Chief Executive Officer and President of Pluri. “We foresee the potential to further develop and bring to market our own proprietary placental-derived MAIT cell immunotherapy platform to revolutionize solid tumor treatment, as well as supporting others in commercializing their immunotherapy treatments.”
Pluri's Placental Allogeneic MAIT Platform
Offering substantial potential benefits compared to conventional T cells, Pluri’s MAIT cells are isolated from the human placenta, a source rich in highly potent allogeneic immune cells. These cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional T cells typically collected from peripheral blood, Pluri’s MAIT cells demonstrate a lower alloreactivity profile. This characteristic not only minimizes their likelihood of inducing Graft versus Host Disease, a significant advantage over other potential allogeneic products, but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy.
When combined with Pluri's 3D cell expansion technology, we believe that the MAIT platform will enable commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patients.
About Pluri’s 3D Immune Cell Expansion Technology
Pluri's novel technology represents a paradigm shift in immune cell expansion methodologies because, unlike traditional approaches, its method employs a fundamentally different concept. Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality. We believe that this innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a potentially promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers Contract Development and Manufacturing Organization services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential of its MAIT platform and its ability to enable commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patients; the potential size of the global immune cell engineering market and the global cancer immunotherapy market; the belief that it unlocked the full potential of MAIT cells; the belief that the immunotherapy field will emerge; the belief that its IP portfolio will grow; the expectation that its own proprietary placental-derived MAIT cell immunotherapy platform will continue to develop, revolutionize solid tumor treatment and support others in commercializing their immunotherapy treatments; and the potential of Pluri’s 3D immune expansion technology as a solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Berry Brady at berry@quantum-corp.com
FAQ
What are the key benefits of Pluri's (PLUR) MAIT cell technology for cancer treatment?
How many patents does Pluri (PLUR) currently hold in its intellectual property portfolio?
What is the market potential for Pluri's (PLUR) immune cell engineering technology?
What distinguishes Pluri's (PLUR) MAIT cells from conventional T cells?
